Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
Clinical trial NCT07485296 · RECRUITING
Trial details
- NCT number
- NCT07485296
- Sponsor
- Gruppo Oncologico del Nord-Ovest
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-27
- Primary completion
- 2030-12-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.